STOCK TITAN

Virpax Pharmaceuticals, Inc. - VRPX STOCK NEWS

Welcome to our dedicated page for Virpax Pharmaceuticals news (Ticker: VRPX), a resource for investors and traders seeking the latest updates and insights on Virpax Pharmaceuticals stock.

Virpax Pharmaceuticals, Inc. (symbol: VRPX) is a pioneering biopharmaceutical company dedicated to developing advanced drug delivery systems aimed at improving patient compliance and achieving therapeutic efficacy. Specializing in non-opioid pain management, Virpax is committed to enhancing patients' quality of life through innovative pharmaceutical products.

As a preclinical stage company, Virpax focuses on creating branded pharmaceutical products for pain management. Their impressive product portfolio includes:

  • Topical Metered-Dose Spray: A novel approach for localized pain relief.
  • Liposomal in Hydrogel Encapsulation: A cutting-edge technology designed to enhance drug delivery and efficacy.
  • Enkephalin Intranasal Spray: An innovative treatment method aimed at providing rapid pain relief.

Virpax Pharmaceuticals collaborates with a network of U.S. and global partners to advance the development of its proprietary drug platforms. Their goal is to become a global leader in non-opioid pain management, creating value for investors and partners alike.

Recent achievements and current projects highlight Virpax’s commitment to innovation. These include advancing their drug candidates through preclinical stages, securing strategic partnerships, and working towards regulatory approvals.

Financially, Virpax Pharmaceuticals is focused on sustainable growth, leveraging cutting-edge technology to develop products that meet the unmet needs of pain management patients. The company’s strategic initiatives are designed to enhance shareholder value while pushing the boundaries of pharmaceutical advancements.

Stay tuned for the latest updates and exciting developments from Virpax Pharmaceuticals as they continue to make strides in the biopharmaceutical industry.

Rhea-AI Summary

Virpax Pharmaceuticals (NASDAQ: VRPX) announced successful toxicology and pharmacokinetic study results for Epoladerm™, aimed at managing knee osteoarthritis pain. Conducted by Charles River Laboratories, the study demonstrated that Epoladerm was well-tolerated, with no adverse effects observed in minipigs. Plasma levels confirmed effective transdermal absorption, peaking at four hours post-dose and remaining detectable after 24 hours. These findings are expected to bolster the Company’s IND filing, paving the way for upcoming first-in-human clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.12%
Tags
none
-
Rhea-AI Summary

Virpax Pharmaceuticals (NASDAQ:VRPX) reported its financial results for Q3 and YTD 2021, highlighting a $40 million public offering that bolstered its balance sheet. The company aims to expedite its product pipeline, focusing on indications for pain, CNS disorders, and antiviral applications. Cash reserves stand at $41.7 million, enabling progress on IND filings for candidates like Epoladerm and Envelta. Operating losses grew to $3.2 million for Q3, up from $1.7 million a year prior, driven by rising operating expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
-
Rhea-AI Summary

Virpax Pharmaceuticals (NASDAQ: VRPX) has announced the award of research and development contracts by the National Center for Advancing Translational Sciences (NCATS) to support the Good Manufacturing Practices (GMP) production of its drug Envelta. This includes the procurement of devices for preclinical studies and the manufacturing of the active ingredient L-ENK. Envelta is designed for pain management and is part of Virpax’s ongoing development efforts for non-addictive pain relief alternatives. The company plans to submit an IND package to the FDA to initiate human trials once the studies are completed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.24%
Tags
none
Rhea-AI Summary

Virpax Pharmaceuticals (NASDAQ: VRPX) announced an agreement with Sinclair Research to conduct preclinical studies of AnQlar™, an over-the-counter prophylactic aimed at combating SARS and influenza. These studies will assess method, dosage, and toxicity for an Investigational New Drug Application, expected to commence in January 2022. CEO Anthony Mack emphasized the significance of this step in advancing their anti-viral pipeline. AnQlar is a chitosan derivative that may inhibit viral replication and entry into cells, showcasing potential in managing viral infections.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
none
-
Rhea-AI Summary

Virpax Pharmaceuticals (NASDAQ: VRPX), focused on pain management and CNS disorders, announced that its Chairman and CEO, Anthony P. Mack, will present at the Pain Management Virtual Investor Forum on October 7, 2021, at 9:00 a.m. Eastern time. The event will be moderated by Gregory Aurand from Noble Capital Markets. Registration is free, and the presentation will be archived on Channelchek and Virpax's investor page. Virpax is known for its non-addictive pain management products and is pursuing FDA approval for innovative drug delivery systems.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.38%
Tags
conferences
-
Rhea-AI Summary

Virpax Pharmaceuticals (NASDAQ:VRPX) has acquired exclusive global rights to Nanomerics' molecular envelope platform technology for the nasal delivery of cannabidiol (CBD) aimed at managing epilepsy in patients aged one year and older. The investigational product, VRP324, will utilize a unique device for intranasal CBD transport, targeting severe epilepsy syndromes. Preclinical studies are underway, and successful results may lead to an FDA application. This acquisition marks a strategic expansion into neurology, enhancing Virpax's innovative drug delivery platforms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.06%
Tags
none
Rhea-AI Summary

Virpax Pharmaceuticals (NASDAQ:VRPX) has completed an underwritten public offering of 6,670,000 shares at $6.00 each, raising gross proceeds of $40,020,000. An option for underwriters to purchase an additional 1,000,500 shares is also available. The funds will support R&D for multiple product candidates, repay notes, pay deferred compensation to the CEO, and cover general corporate expenses. ThinkEquity served as the sole book-running manager for the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
-
Rhea-AI Summary

Virpax Pharmaceuticals (NASDAQ:VRPX) has announced the pricing of an underwritten public offering of 6,670,000 shares at $6.00 per share, totaling approximately $40 million before expenses. The company has also granted underwriters a 45-day option for an additional 1,000,500 shares. Proceeds will fund research and development for their pain management products, including Epoladerm and Probudur, and cover expenses related to the offering. ThinkEquity is the sole book-running manager for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-36.82%
Tags
-
Rhea-AI Summary

Virpax Pharmaceuticals (NASDAQ:VRPX) announced the presentation of a poster on Leucine Enkephalin as a potential analgesic at PAINWeek 2021 from September 7-11, 2021 in Las Vegas, NV. The poster, titled Enkephalin as a Potential Analgesic, will be presented by Dr. Jeffrey A. Gudin on September 9. Envelta™, the intranasal formulation of enkephalin, aims to manage pain without the adverse effects linked to opioid use. Supported by a NIH partnership, animal trials suggest its efficacy comparable to morphine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
none
Rhea-AI Summary

Virpax Pharmaceuticals (NASDAQ:VRPX) announced a manufacturing agreement with Seqens for the supply of MMS019, a novel drug for pain management. This collaboration ensures both clinical and long-term commercial supply, enhancing development capabilities. MMS019 utilizes advanced nanotechnology to deliver medication intranasally, showing promising preclinical results comparable to morphine without associated drug-seeking behavior. Virpax is also advancing other programs like Envelta™ for pain management and PES200 for PTSD, indicating a strong focus on innovative, non-addictive therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
none

FAQ

What is the current stock price of Virpax Pharmaceuticals (VRPX)?

The current stock price of Virpax Pharmaceuticals (VRPX) is $0.33 as of December 20, 2024.

What is the market cap of Virpax Pharmaceuticals (VRPX)?

The market cap of Virpax Pharmaceuticals (VRPX) is approximately 2.7M.

What does Virpax Pharmaceuticals, Inc. specialize in?

Virpax specializes in developing advanced drug delivery systems for pain management, focusing on non-opioid therapies.

What are some of Virpax Pharmaceuticals' key products?

Key products include a topical metered-dose spray, liposomal in hydrogel encapsulation, and an enkephalin intranasal spray.

Is Virpax Pharmaceuticals a preclinical stage company?

Yes, Virpax Pharmaceuticals is currently a preclinical stage biopharmaceutical company.

What is Virpax's goal in the pharmaceutical industry?

Virpax aims to become a global leader in non-opioid pain management by developing innovative pharmaceutical products.

How does Virpax enhance the efficacy of its products?

Virpax uses cutting-edge technology in its drug delivery systems to improve patient compliance and therapeutic efficacy.

Who does Virpax collaborate with for its developments?

Virpax collaborates with a network of U.S. and global partners to advance its proprietary drug platforms.

What type of spray is included in Virpax's product portfolio?

Virpax's product portfolio includes a topical metered-dose spray and an enkephalin intranasal spray.

How is Virpax Pharmaceuticals enhancing shareholder value?

Virpax focuses on sustainable growth and strategic initiatives to enhance shareholder value while advancing pharmaceutical innovations.

What technology does Virpax use for drug encapsulation?

Virpax uses liposomal in hydrogel encapsulation technology for enhanced drug delivery and efficacy.

Where can I find the latest news about Virpax Pharmaceuticals?

The latest news and updates on Virpax Pharmaceuticals can be found on financial news websites and the company's official announcements.

Virpax Pharmaceuticals, Inc.

Nasdaq:VRPX

VRPX Rankings

VRPX Stock Data

2.72M
7.79M
3.72%
1.9%
7.18%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BERWYN